Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Gyre Therapeutics Inc.(GYRE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GYRE
11/10/2026: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Gyre Therapeutics Inc. is a clinical-stage biotechnology company focused on developing Hydronidone for liver fibrosis, a significant medical market. The company’s primary strength lies in its specialized focus and potential for growth tied to the success of its lead candidate. Its investment story is characterized by high-risk, high-reward prospects dependent on favorable clinical trial data and regulatory outcomes. Key risks include intense competition from established pharmaceutical players, the binary nature of clinical trials, and the potential for equity dilution. The stock best suits investors with a high risk tolerance, and observers should monitor upcoming clinical trial readouts for material impact on the company's valuation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential tied to clinical milestones. |
| Momentum investor | Mixed fit | Can be a fit during positive clinical update cycles but remains volatile. |
| Value investor | Weak fit | Lack of earnings and product revenue makes traditional valuation metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and requires all capital for development. |
| Low-risk investor | Weak fit | High volatility and the inherent risks of clinical-stage biotechnology are not suitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to clinical trial news and biotech sector sentiment. |
| Valuation risk | High | Valuation is speculative and based on the potential future success of a single lead candidate. |
| Competition risk (liver disease) | High | The company competes with established pharmaceutical giants with significantly larger budgets. |
| Business quality | Medium | The company is transitioning and needs to prove the commercial viability of its pipeline. |
| Dividend income | Low / none | There is no income component to the investment. |
| Execution risk | High | Success depends entirely on the successful completion of complex, long-term clinical trials. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -69% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 508.95M USD | Price to earnings Ratio - | 1Y Target Price 18.67 |
Price to earnings Ratio - | 1Y Target Price 18.67 | ||
Volume (30-day avg) 171.1K shares | Beta 4.92 | 52 Weeks Range 3.97 - 9.14 | Updated Date 11/09/2026 |
52 Weeks Range 3.97 - 9.14 | Updated Date 11/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research and Development | Advancing Hydronidone and potential future pipeline assets. | The company currently does not generate significant product revenue; success depends on future clinical trial outcomes and eventual drug approval. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When After Market | Estimate -0.15 | Actual 0.04 |
Profitability
Profit Margin -22.7% | Operating Margin (TTM) -4.46% |
Management Effectiveness
Return on Assets (TTM) -6.32% | Return on Equity (TTM) -17.17% |
Valuation
Trailing PE - | Forward PE 188.68 | Enterprise Value 441.54M | Price to Sales(TTM) 4.62 |
Enterprise Value 441.54M | Price to Sales(TTM) 4.62 | ||
Enterprise Value to Revenue 3.75 | Enterprise Value to EBITDA 131 | Shares Outstanding 109.45M | Shares Floating 37.80M |
Shares Outstanding 109.45M | Shares Floating 37.80M | ||
Percent Insiders 74.4 | Percent Institutions 8.4 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.